Report Details

Biosimilar monoclonal antibodies - this new study shows you potential sales

What does the future hold for biosimilar therapeutic antibodies? Visiongain's new report predicts revenues to 2023. There you find the best places for sales growth, also understanding trends and opportunities.

In that study you get revenue forecasts at overall world market, submarket, product, and national level. See what's happening for those technologies, finding how you can gain.

Read on, then, to explore biosimilar monoclonal antibodies (mAbs) and see what their future market could be worth.

Forecasts to 2023 and other analyses show you commercial potentials

Besides revenue forecasting, our new work shows recent results, growth rates, and market shares. You discover original quantitative and qualitative analysis, seeing business outlooks and developments (R&D). You also get 69 tables, 52 charts, and two research interviews.

Is finding data for biosimilar mAbs a challenge? Avoid falling behind. You can now stay ahead in knowledge, benefiting your research, analyses, and decisions. Also save time.

There you investigate follow-on protein technology for antibodies. You hear what's happening and see where the money lies. Finding that data just got easier.

The following sections, then, show what you get in our research and analysis.

Prospects for the world market and submarkets for those follow-on biologics

Our new report shows revenue to 2023 for the overall world market. It also shows you individual forecasts of seven biosimilar mAb submarkets:
• Infliximab
• Rituximab
• Adalimumab
• Trastuzumab
• Bevacizumab
• Abciximab
• Other molecules (grouped analysis).

How will the biosimilar mAbs market expand? Which parts will most prosper? There you assess prospects for revenue growth.

Our study gives you a feel for what stimulates and restrains that industry and market. That analysis helps you identify potential and find ways for your business to develop.

You also find revenue predictions for products using follow-on antibody technology.

Forecasts for 13 agents - assess potential of existing and expected products

How will products perform to 2023 at world level? Our report forecasts individual revenues of 13 biosimilar antibodies, launched or in development, including these:
• Celltrion's Remsima
• Dr. Reddy's Reditux
• Epirus Biopharmaceuticals' BOW-015
• Boehringer Ingelheim's BI695500 and BI695501
• Fujifilm Kyowa Kirin Biologics' forms of adalimumab and bevacizumab
• Biocon's Bmab200
• BIOCAD's BCD-022
• Isu Abxis's Clotinab
• Reliance Life Sciences' R-TPR-019.

There you discover how high sales can go, to 2023, finding products and years with highest predicted growth and revenues. Also you compare competitors. You see what's happening, then, understanding trends, competition, challenges, and opportunities.

Our investigation also divides its overall world forecast into geographical regions.

National markets - what outlooks for sales?

Developments worldwide expand the biosimilar mAbs market. Hear about the best revenue prospects.

In developed and developing countries, many opportunities for producers of those biological drugs will occur from 2013 to 2023. See where and how.

Our analyses show you individual revenue forecasts to 2023 for 12 national markets:
• US and Japan
• Germany, France, UK, Italy, and Spain (EU5)
• China, India, Brazil, Russia (BRIC), and South Korea.

There you discover progress and outlooks. Product launches from 2013 to 2023 will change the commercial landscape. See how, finding what affects that biologics segment.

Issues affecting biosimilar antibody manufacturing and selling

Our report also shows you issues and events affecting that industry

Table Of Contents

Biosimilar Monoclonal Antibodies: World Market Prospects 2013-2023
Table of Contents

1. Executive Summary
1.1 What This Report Covers
1.2 Biosimilar MAbs: World Market Overview 2013-2023
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. Introduction to Biosimilar Monoclonal Antibodies
2.1 Natural Antibodies: Key to the Immune System
2.2 From Serum Therapy to Monoclonal Antibodies (MAbs)
2.3 Humanising the MAb
2.4 Biologics and Biosimilars
2.5 Why are Biosimilars in Demand?
2.6 Considerations for the Development of Biosimilars
2.6.1 Biologics and Biosimilars Are Large, Complex Molecules
2.6.2 How Big a Concern Is Immunogenicity?
2.7 Biosimilar Monoclonal Antibodies Already on the Market

3. World Market Prospects for Biosimilar Monoclonal Antibodies, 2013-2023
3.1 The World Market for Biosimilar Monoclonal Antibodies in 2012: 3 Biosimilar MAbs on the Market
3.2 The World Market for Biosimilar MAbs: An Overarching Revenue Forecast, 2013-2023
3.3 The World Market for Biosimilar MAbs by Compound: Revenue and Market Share Predictions, 2018 and 2023
3.4 The World Market for Biosimilar MAbs by Compound: Grouped Revenue Forecast, 2013-2023
3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
3.4.2 Biosimilar Infliximab: High Growth Expected in 2013 Biosimilar Infliximab: Revenue Forecast, 2013-2023
3.4.3 Biosimilar Rituximab: With So Many Compounds Under Development, Will Growth Be Driven or Restrained? Biosimilar Rituximab: Revenue Forecast, 2013-2023
3.4.4 Biosimilar Abciximab: Low Market Incentive Means Few Compounds Are in Development Biosimilar Abciximab: Revenue Forecast, 2013-2023
3.4.5 Biosimilar Trastuzumab: The 4th Biosimilar MAb to Enter the Market Biosimilar Trastuzumab: Revenue Forecast, 2013-2023
3.4.6 Biosimilar Adalimumab: Great Incentive to Develop Biosimilar Versions of the Leading Drug of 2012 Biosimilar Adalimumab: Revenue Forecast, 2013-2023
3.4.7 Biosimilar Bevacizumab: Will Late Entry to the Market Restrict Revenue Generation? Biosimilar Bevacizumab: Revenue Forecast, 2013-2023
3.5 Large Market Potential to Drive Growth to 2023
3.6 What Will Restrain the Growth of the Biosimilar MAbs Market Between 2013 and 2023?

4. Promising Biosimilar MAb Products and Their Predicted Future Success, 2013-2023
4.1 Biosimilar Versions on the Market: Remsima Dominates in 2012
4.1.1 Celltrion's Remsima (infliximab): The First Official Biosimilar Monoclonal Antibody
4.1.2 Dr. Reddy's Reditux (rituximab): Are US and EU Approval Expected?
4.1.3 Probiomed's Kikuzubam (rituximab): On the Market in South America
4.1.4 Instas Pharmaceuticals' Mabtas (rituximab)
4.1.5 Isu Abxis' Clotinab (abciximab): The First Biosimilar Monoclonal Antibody?
4.2 Biosimilar Versions on the Market and Promising Compounds in the Pipeline: Market Forecast, 2013-2023
4.2.1 Celltrion's Remsima (infliximab): Revenue Forecast, 2013-2023
4.2.2 Epirus Biopharmaceuticals' BOW-015 (infliximab): Revenue Forecast, 2013-2023
4.2.3 Dr. Reddy's Reditux (rituximab): Revenue Forecast, 2013-2023
4.2.4 Boehringer Ingelheim's BI695500 (rituximab): Revenue Forecast, 2013-2023
4.2.5 Celltrion's CT-P10 (rituximab): Revenue Forecast, 2013-2023
4.2.6 Boehringer Ingelheim's BI695501 (adalimumab): Revenue Forecast, 2013-2023
4.2.7 Fujifilm Kyowa Kirin Biologics' adalimumab: Revenue Forecast, 2013-2023
4.2.8 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue Forecast, 2013-2023
4.2.9 Celltrion's CT-P06 (trastuzumab): Revenue Forecast, 2013-2023
4.2.10 Biocon's Bmab200 (trastuzumab): Revenue Forecast, 2013-2023
4.2.11 BIOCAD's BCD-022 (trastuzumab): Revenue Forecast, 2013-2023
4.2.12 Isu Abxis' Clotinab (abciximab): Revenue Forecast, 2013-2023
4.2.13 Reliance Life Sciences' R-TPR-019 (abciximab): Revenue Forecast, 2013-2023


View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints ...

PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • December 2014
  • by Global Data

PharmaPoint: Rheumatoid Arthritis - 5EU Drug Forecast and Market Analysis to 2023 Summary Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints. ...

Biosimilars: Global Markets

Biosimilars: Global Markets

  • $ 6 650
  • Industry report
  • January 2015
  • by BCC Research

REPORT HIGHLIGHTS The global biosimilars market was valued at $1.8 billion in 2013 and nearly $2.0 billion in 2014. The market is expected to reach nearly $4.0 billion by 2019, with a compound annual growth ...

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.